Rigel Pharmaceuticals, Inc. Stock News

Pooled ARROW and TAPISTRY analysis demonstrated a 53% overall response rate in patients with RET fusion-positive solid tumors Additional analyses highlight first-line clinical outcomes and patient-reported quality of life in RET fusion-positive NSCLC and efficacy and safety in RET fusion-positive thyroid cancer SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, In...

SOUTH SAN FRANCISCO, Calif., Oct. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDAQ...

VEPPANU is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated mBC SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced VEPPANUTM (vepdegest...

Second quarter 2026 total revenues of $78.7 million, including net product sales of $67.0 million and contract revenues from collaborations of $11.7 million, and net income of $17.3 million Expanded commercial portfolio with the in-license of VEPPANU™ (vepdegestrant), with U.S. commercial availability expected in mid-August Advanced R289 development program; Phase 1b study in patients with lowe...

SOUTH SAN FRANCISCO, Calif., July 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDAQ...

Dr. Hannah has decades of oncology drug development experience and has served on Rigel's Board of Directors since 2021 She has resigned from Rigel's Board of Directors to join the company SOUTH SAN FRANCISCO, Calif., July 1, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the a...

SOUTH SAN FRANCISCO, Calif., June 16, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of its license agreement for VEPPANUTM (vepdegestrant), following the early termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976 and sat...